Molinalogo

Measure / Data Element

2020

2021

2021 Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

69.52%

71.79%

67.60%

Annual Dental Visits (ADV)

NB

NB

50.00%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

41.87%

42.12%

42.90%

Appropriate Testing for Pharyngitis (CWP)

46.59%

44.96%

80.70%

Appropriate Treatment for Upper Respiratory Infection (URI)

90.21%

90.58%

90.80%

Asthma Medication Ratio (AMR) Total

56.22%

60.39%

68.40%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB)

48.51%

50.02%

59.50%

Breast Cancer Screening (BCS)

60.45%

55.83%

56.70%

Cervical Cancer Screening (CCS)

58.88%

57.18%

62.00%

Childhood Immunization Status (CIS) Combination #10

38.44%

40.15%

42.30%

Chlamydia Screening in Women (CHL) Total

65.11%

61.24%

60.10%

Comprehensive Diabetes Care (CDC) BP Control < 140/90

67.40%

54.26%

63.20%

Comprehensive Diabetes Care (CDC) HbA1c Control <8.0%

51.09%

50.12%

49.60%

Comprehensive Diabetes Care (CDC) Eye Exam

60.83%

59.85%

55.80%

Controlling High Blood Pressure (CBP)

61.31%

54.99%

60.00%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

80.95%

76.33%

78.90%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

NB

3.84%

16.30%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

NB

11.10%

45.40%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

NB

NB

44.80%

Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase

39.81%

39.05%

60.30%

Immunizations for Adolescents (IMA) Combination #2

36.98%

39.42%

41.80%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total

4.01%

NB

16.50%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Total

NA

NA

34.80%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

68.35%

65.38%

73.60%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

83.06%

82.82%

86.90%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

95.62%

89.29%

88.30%

Prenatal and Postpartum Care (PPC) Postpartum Care

75.91%

78.10%

78.30%

Risk of Continued Opioid Use (COU) 31-Day Total

3.44%

3.54%

≤ 2.80%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

80.78%

80.20%

81.90%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

71.87%

75.95%

74.90%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

68.76%

71.02%

68.50%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

65.35%

69.67%

71.90%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

NA

NA

66.40%

Use of Imaging Studies for Low Back Pain (LBP)

72.77%

74.70%

77.80%

Use of Opioids at High Dosage (HDO)

3.92%

3.17%

≤ 2.90%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

2.61%

1.81%

≤ 1.30%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

86.37%

86.86%

80.60%